https://www.businesswire.com/news/home/20221108005267/en/New-Inventprise-Pneumococcal-Vaccine-Enters-Phase-12-Clinical-Evaluation
Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has beg
Create an account or login to join the discussion